Article Text

Download PDFPDF

P02.05 How proton pump inhibitors blunt immune checkpoint inhibitors efficacy: a role of the microbiome?
  1. E Ramel1,
  2. M Masson1,
  3. D Challopin1,2,
  4. A Barre2,
  5. M Nikolski2,
  6. M Kostine1,3 and
  7. M Saleh1,4
  1. 1ImmunoConcEpT, Bordeaux, France
  2. 2CBiB, Bordeaux, France
  3. 3University of Bordeaux Hospital, Division of Rheumatology, Pellegrin Hospital, Bordeaux, France
  4. 4Adjunct Professor, Department of Medicine, McGill University, Montreal, QC, Canada


Background While Immune checkpoint inhibitors (ICIs) are revolutionizing the management of many advanced cancers, several studies have reported that the gut microbiota composition may have an impact on ICI response. Antibiotics have been shown to alter the efficacy of immunotherapies, but other commonly used comedications known to interact with the microbiota might also impact the clinical benefit of those treatments. Clinical studies revealed that patients treated with ICI could be stratified into responder (R) or non-responder (NR) according to their microbiota composition. In a total of 635 patients with advanced cancer treated with anti PD-1, anti PD-L1 or anti CTLA-4 between 2015 and 2017 in Bordeaux, M. Kostine et al. described an association between the baseline use of co-medications, including proton pump inhibitors (PPIs), and a significantly shortened overall survival.1 Our objectives are a) to address whether PPIs impact the ICI response, and b) to understand if the underlying mechanism involves the gut microbiota.

Materials and Methods We first explored the impact of the PPI omeprazole on the composition of the microbiota in different segments of the gut. This was conducted in mice after long- or short-time exposure to omeprazole. In parallel, we explored omeprazole-induced changes in the intestinal transcriptome using bulk RNA sequencing of gut tissue segments. In other experiments, we interrogated the impact of omeprazole on anti-PD-1 efficacy in mice transplanted with different cancer cell-lines. Using 16S rDNA sequencing, we characterized both the gut as well as the local tumor microbiomes of R and NR mice.

Results Our results revealed that omeprazole treatment resulted in a decrease of bacteria associated with a healthy gut and an expansion of oral bacteria and environmental pathobionts, consistent with published studies.2, 3 Notably, omeprazole administration led to a striking reduction in Lachnospiraceae spp., which are enriched in the ‘microbiotype’ of ICI-responder patients.4 Multi-omics integration of the gut microbiome and transcriptional data sets using weighted gene co-expression network analysis (WGCNA) identified omeprazole-induced transcriptional modules in the colon significantly associated with depletion or enrichment of specific microbiota components. From this integration, we will reconstruct the bacterial and host metabolic networks towards identifying metabolic signals linked to impaired anti-tumor immunity.

Conclusions Collectively, our results present the impact of PPI on microbiome changes in tumor-bearing individuals and unravel potential mechanisms for intervention aimed at enhancing the anti-tumoral immune responses elicited by immunotherapies.


  1. Kostine, M. et al. Eur J Cancer 2021;157:474–484. PMID: 34649118.

  2. Imhann, F. et al. Gut 2016;65:740–748. PMID: 26657899.

  3. Jackson, M. A. et al. Gut 2016;65:749–756. PMID: 26719299.

  4. McCulloch, J. A., et al. Nat Med 2022;28:545–556. PMID: 35228752.

Disclosure Information E. Ramel: None. M. Masson: None. D. Challopin: None. A. Barre: None. M. Nikolski: None. M. Kostine: None. M. Saleh: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.